Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor.
- Author:
Wei JIN
1
;
Yi-rang HUANG
Author Information
1. Department of Urology, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China. jw1230123@sina.com
- Publication Type:Journal Article
- MeSH:
Carbolines;
therapeutic use;
Erectile Dysfunction;
drug therapy;
etiology;
Humans;
Imidazoles;
therapeutic use;
Male;
Phosphodiesterase Inhibitors;
therapeutic use;
Piperazines;
therapeutic use;
Prostatectomy;
adverse effects;
Purines;
therapeutic use;
Sildenafil Citrate;
Sulfones;
therapeutic use;
Tadalafil;
Triazines;
therapeutic use;
Vardenafil Dihydrochloride
- From:
National Journal of Andrology
2005;11(9):708-712
- CountryChina
- Language:Chinese
-
Abstract:
The rate of erectile dysfunction after radical retropubic prostatectomy is from 10% to 100%. The prevalence of erectile dysfunction after nerve-sparing radical prostatectomy is more than one third. In the patients who had undergone bilateral NS, 72% responded to sildenafil, 71.7% and 59.7% responded to 20 mg and 10 mg of vardenafil respectively. For all randomized patients who received tadalafil, the mean percentage of successful penetration attempts was 54% and the mean percentage of successful intercourse attempts was 41%. For the subgroup with evidence of postoperative tumescence these values were 69% and 52%, respectively. No head-to-head trials have been performed with sildenafil, vardenafil and tadalafil in treatment of erectile dysfunction after radical prostatectomy.
